Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 117

Sort by

Sort Order Select

Journal Articles

Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia

Karen Thudium Mueller, PharmD, MS, Abhijit Chakraborty, PhD, Patricia A Wood, MD PhD, Rakesh Awasthi, BPharm, Alfonso Quintas-Cardama, MD, Xia Han, MS, Shannon L Maude, MD PhD, Stephan A. Grupp, MD PhD, David L Porter, MD, Noelle Frey, MD MS, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Jan J. Melenhorst, PhD, Carl H June, MD, Simon F. Lacey, PhD

Blood (2016) 128 (22): 220.

https://doi.org/10.1182/blood.V128.22.220.220

Published: 2016

Journal Articles

Developing Therapeutic Strategies for CLL with Mutant p53

Hun Ju Lee, MD, Miguel Gallardo, PhD, Xiaorui Zhang, BS, Huaxian Ma, BS, Alfonso Quintas-Cardama, MD, Yuan Qi, Xiaoping Su, PhD, Sean M. Post, PhD

Blood (2015) 126 (23): 2476.

https://doi.org/10.1182/blood.V126.23.2476.2476

Published: 2015

Journal Articles

hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML

Miguel Gallardo, PhD, Hun Ju Lee, MD, Xiaorui Zhang, BS, Carlos E. Bueso-Ramos, MD, Laura Pageon, Mark McArthur, Asha Multani, Aziz Nazha, MD, Taghi Manshouri, PhD, Jan Parker-Thornburg, Peter Hu, Yuan Qi, Xiaoping Su, PhD, Inmaculada Rapado, Alfonso Quintás-Cardama, Steven M. Kornblau, MD, Joaquin Martinez-López, MDPhD, Sean M. Post, PhD

Blood (2015) 126 (23): 439.

https://doi.org/10.1182/blood.V126.23.439.439

Published: 2015

Journal Articles

hnRNP K Overexpression Synergizes with Mutant NPM1 to Drive Acute Myeloid Leukemia Progression

Miguel Gallardo, PhD, Hun Ju Lee, MD, Xiaorui Zhang, Laura R. Pageon, Asha Multani, Markus Reschke, PhD, John G Clohessy, Alfonso Quintás-Cardama, MD, Michael Andreeff, MD PhD, Steven M. Kornblau, MD, Pier Paolo Pandolfi, MD PhD, Sean M. Post, PhD

Blood (2014) 124 (21): 2382.

https://doi.org/10.1182/blood.V124.21.2382.2382

Published: 2014

Journal Articles

hnRNP K : A Tumor Suppressor or Oncogene?

Miguel Gallardo, PhD, Hun Ju Lee, MD, Carlos E. Bueso-Ramos, MD PhD, Xiaorui Zhang, Laura R. Pageon, Asha Multani, Inmaculada Rapado, Alfonso Quintás-Cardama, MD, Steven M. Kornblau, MD, Joaquin Martinez-Lopez, Sean M. Post, PhD

Blood (2014) 124 (21): 259.

https://doi.org/10.1182/blood.V124.21.259.259

Published: 2014

Journal Articles

Adverse Prognosis Of Extramedullary Disease In Patients With Chronic Myeloid Leukemia (CML) In The Tyrosine Kinase Inhibitor (TKI) Era: a Cohort Study Of 283 Blastic Phase CML Patients

Young Kwang Chae, MD, MPH, Hagop M Kantarjian, MD, Muhamed Baljevic, MD, Alfonso Quintás-Cardama, MD, Gautam Borthakur, MBBS, Tapan M. Kadia, MD, Susan O'Brien, MD, Carlos G. Romo, M.D., Sherry R. Pierce, RN, BS, Elias Jabbour, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2724.

https://doi.org/10.1182/blood.V122.21.2724.2724

Published: 2013

Journal Articles

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Carlos Guillermo Romo, MD, Rajyalakshmi Luthra, PhD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Sherry Pierce, Farhad Ravandi, MBBS, Susan M. O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2727.

https://doi.org/10.1182/blood.V122.21.2727.2727

Published: 2013

Journal Articles

Analysis Of Responses (complete cytogenetic response and major molecular response) Achieved With Different Tyrosine Kinase Inhibitor (TKI) Modalities and Their Impact On Long Term Outcomes In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) – Analysis From a Single Institution

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Mona Lisa Alattar, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Carlos Guillermo Romo, MD, Sara E Dellasala, RN, Sherry Pierce, Srdan Verstovsek, MD, PhD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2728.

https://doi.org/10.1182/blood.V122.21.2728.2728

Published: 2013

Journal Articles

Safety, Pharmacokinetics, and Efficacy Of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) In Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD, PhD, Elias Jabbour, MD, Marina Konopleva, MD, PhD, Susan O'Brien, MD, Alfonso Quintas-Cardama, MD, Bradley G. Somer, MD, Ana Tari, PhD, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2679.

https://doi.org/10.1182/blood.V122.21.2679.2679

Published: 2013

Journal Articles

p53 Pathway Alterations Influence Survival and Treatment Response In Chronic Lymphocytic Leukemia

Hun Ju Lee, MD, Miguel Gallardo, PhD, Xiaorui Zhang, Alfonso Quintas-Cardama, Sean M. Post, PhD

Blood (2013) 122 (21): 2885.

https://doi.org/10.1182/blood.V122.21.2885.2885

Published: 2013

Journal Articles

Expanded Access Program Of Ponatinib (AP24534) For Patients (Pts) With Refractory Chronic Myeloid Leukemia (CML) Or Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Ghayathri Jeyakumar, MD, Hagop M. Kantarjian, MD, Kendra L. Sweet, MD, Cecilia Y Arana Yi, MD, Nitin Jain, MD, Elias Jabbour, MD, Alfonso Quintas-Cardama, MD, Susan O'Brien, MD, Brenda Walker, RN, Sherry R. Pierce, RN, BS, Tapan M. Kadia, MD, Farhad Ravandi, MD, Javier Pinilla, Jorge E. Cortes, MD

Blood (2013) 122 (21): 4044.

https://doi.org/10.1182/blood.V122.21.4044.4044

Published: 2013

Journal Articles

Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Jorge E. Cortes, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Alfonso Quintas-Cardama, MD, Farhad Ravandi, MD, Evguenia Gachimova, Zeev Estrov, MD, Elias Jabbour, MD, Susan O'Brien, MD, Hagop Kantarjian, MD

Blood (2013) 122 (21): 1483.

https://doi.org/10.1182/blood.V122.21.1483.1483

Published: 2013

Journal Articles

Estimated Glomerular Filtration Rate Changes In Patients (Pts) With Chronic Myeloid Leukemia (CML) Treated With Tyrosine Kinase Inhibitors (TKI)

Musa Yilmaz, MD, Hagop M. Kantarjian, MD, Alfonso Quintas-Cardama, MD, Susan O'Brien, MD, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Gautam Borthakur, MBBS, Farhad Ravandi, MD, Sherry Pierce, Elias Jabbour, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 1488.

https://doi.org/10.1182/blood.V122.21.1488.1488

Published: 2013

Journal Articles

Clinical Safety and Efficacy Of Nilotinib Or Dasatinib In Patients (Pts) With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) With Pre-Existing Liver and/Or Renal Dysfunction

Koji Sasaki, MD, Hagop M Kantarjian, MD, Elias Jabbour, MD, Alfonso Quintas-Cardama, MD, Sherry Pierce, Gautam Borthakur, MD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Alessandra Ferrajoli, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 1500.

https://doi.org/10.1182/blood.V122.21.1500.1500

Published: 2013

Journal Articles

Relative RATIO Of BCR-ABL1 Transcript Clearance Improves The Prognostic VALUE Of Single PCR Assessment At The 3 and 6 Month Time Points In Patients With Chronic Myeloid Leukemia In Chronic PHASE Treated In The Dasision Study

Alfonso Quintás-Cardama, MD, Sangbum Choi, PhD, Hagop M. Kantarjian, MD, Xuelin Huang, Jorge E. Cortes, MD

Blood (2013) 122 (21): 3993.

https://doi.org/10.1182/blood.V122.21.3993.3993

Published: 2013

Journal Articles

Outcome Of Patients (pts) With Myelofibrosis (MF) After Ruxolutinib (Rux) Therapy

Elias Jabbour, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Alfonso Quintas-Cardama, Marylou Cardena-Turanzas, Susan O'Brien, MD, Jorge E. Cortes, MD, Nitin Jain, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Mark Brandt, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 1584.

https://doi.org/10.1182/blood.V122.21.1584.1584

Published: 2013

Journal Articles

Differential Prognostic Impact Of Peripheral Blood Blast Clearance In AML Based On Type Of Therapy and FLT3 Mutation Status

Christopher B. Benton, MD, Lisa Gu, Hagop M. Kantarjian, MD, Peng Qiu, PhD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Sherry Pierce, Mark Brandt, Marina Konopleva, MD, PhD, Jorge E. Cortes, MD, Michael Andreeff, MD, PhD, Alfonso Quintas-Cardama, MD

Blood (2013) 122 (21): 2584.

https://doi.org/10.1182/blood.V122.21.2584.2584

Published: 2013

Journal Articles

Symptom Burden In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Loretta A. Williams, PhD, RN, Patricia S. Ault, MS, ACNP, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Alfonso Quintas-Cardama, MD, Gautam Borthakur, MD, Stefan H. Faderl, MD, Elias J. Jabbour, MD, Charles S. Cleeland, PhD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2988.

https://doi.org/10.1182/blood.V122.21.2988.2988

Published: 2013

Journal Articles

Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Carlos Guillermo Romo, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Sherry Pierce, Mary Joy Liboon, Evguenia Gachimova, Tapan M. Kadia, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 4019.

https://doi.org/10.1182/blood.V122.21.4019.4019

Published: 2013

Journal Articles

A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS

Courtney D. DiNardo, MD, Hagop M Kantarjian, MD, Farhad Ravandi, MD, Marina Konopleva, MD, PhD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Naval G. Daver, MD, Menda Durand, MSN, RN, Silvia Rivera, MS, Alfonso Quintás-Cardama, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2698.

https://doi.org/10.1182/blood.V122.21.2698.2698

Published: 2013

NARROW

Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia

Developing Therapeutic Strategies for CLL with Mutant p53

hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML

hnRNP K Overexpression Synergizes with Mutant NPM1 to Drive Acute Myeloid Leukemia Progression

hnRNP K : A Tumor Suppressor or Oncogene?

Adverse Prognosis Of Extramedullary Disease In Patients With Chronic Myeloid Leukemia (CML) In The Tyrosine Kinase Inhibitor (TKI) Era: a Cohort Study Of 283 Blastic Phase CML Patients

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Analysis Of Responses (complete cytogenetic response and major molecular response) Achieved With Different Tyrosine Kinase Inhibitor (TKI) Modalities and Their Impact On Long Term Outcomes In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) – Analysis From a Single Institution

p53 Pathway Alterations Influence Survival and Treatment Response In Chronic Lymphocytic Leukemia

Expanded Access Program Of Ponatinib (AP24534) For Patients (Pts) With Refractory Chronic Myeloid Leukemia (CML) Or Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Estimated Glomerular Filtration Rate Changes In Patients (Pts) With Chronic Myeloid Leukemia (CML) Treated With Tyrosine Kinase Inhibitors (TKI)

Clinical Safety and Efficacy Of Nilotinib Or Dasatinib In Patients (Pts) With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) With Pre-Existing Liver and/Or Renal Dysfunction

Relative RATIO Of BCR-ABL1 Transcript Clearance Improves The Prognostic VALUE Of Single PCR Assessment At The 3 and 6 Month Time Points In Patients With Chronic Myeloid Leukemia In Chronic PHASE Treated In The Dasision Study

Outcome Of Patients (pts) With Myelofibrosis (MF) After Ruxolutinib (Rux) Therapy

Differential Prognostic Impact Of Peripheral Blood Blast Clearance In AML Based On Type Of Therapy and FLT3 Mutation Status

Symptom Burden In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution

A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only